Exemplis Discimus 2004, 148(2):171-173

Morbi eros libero, gravida at, pellentesque at, convallis ut, magna.

Tethys Fyra, Sylvain Kellara, Erisi Suavereb, Rika Bolbanc
a 2nd Clinic of Pharmacognosy, Altyr University, Republic of Bogden
b National Institute of Nursing Management, University of Dromund Kaas, Republic of Corellia
c 1st Clinic of Community Health Nursing, Maramere Teaching Hospital, Coruscant Republic

Nullam eu purus nec metus bibendum ullamcorper. Praesent tellus lectus, dignissim quis, pellentesque sit amet, fringilla et, sem. Morbi nisl turpis, fermentum vitae, consectetuer id, sodales ut, sem. Morbi justo diam, hendrerit mollis, tempus et, dapibus quis, leo. Vestibulum varius mauris a risus tempus bibendum. Mauris arcu est, facilisis non, consequat et, gravida sit amet, ligula. Aliquam lectus arcu, iaculis a, bibendum at, dapibus elementum, nisl. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Kµúčové slová: Quisque lacus, Nulla eget purus, Nulla facilisi

Vloľený: August 15, 2004; Přijatý: September 5, 2004; Uverejnené: December 1, 2004 

Zobrazi» celý článok

Referencie

  1. Matsuda S, Koyasu S. (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47, 119-125. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  2. Kovarik JM, Mueller EA, van Bree JB, Fluckiger SS, Lange H, Schmidt B, Boesken WH, Lison AE, Kutz K. (1994). Cyclosporine pharmacokinetics and variability from a microemulsion formulation-- a multicenter investigation in kidney transplant patients. Transplantation 58, 658-663. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  3. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. (1994). Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 83, 444-446. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  4. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. (2001). Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral)1 in organ transplantation. Drugs 61, 1957-2016. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  5. Masri MA, Haberal M, Rizvi A, Stephan A, Bilgin N, Naqvi A, Barbari A, Kamel G, Zafar N, Emiroglu R, Colak T, Manzoor K, Matha V, Kamarád V, Rizk S, Itany AR, Shehedeh I. (2004). The pharmacokinetics of Equoral versus Neoral in stable renal transplant patients: a multinational multicenter study. Transplant Proc 36, 80-83. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  6. Andrýsek T, Masri M, Jegorov A, Veselský Z, Matha V. (2003). Equoral, new cyclosporine drug delivery system, versus Neoral: a bioequivalence study in healthy volunteers. Transplant Proc 35, 207-209. Prejs» k pôvodnému zdroju... Prejs» na PubMed...
  7. Masri MA, Andrýsek T, Matha V. (2003). The role of generics in transplantation. Transplant Proc 35, 2745-2747. Prejs» k pôvodnému zdroju... Prejs» na PubMed...

Spä» na obsah